Diclazuril nonlinear mixed-effects pharmacokinetic modelling of plasma concentrations after oral administration to adult horses every 3–4 days

Laszlo Hunyadi, Mark G. Papich, Nicola Pusterla

Research output: Contribution to journalArticle

Abstract

The purpose of this study was to determine if a low dose of diclazuril (0.5 mg/kg of 1.56% diclazuril pellets) given to six healthy adult horses every 3–4 days for a total of five administrations would achieve steady-state plasma concentrations known to be inhibitory to Sarcocystis neurona and Neospora caninum. Blood was collected via venipuncture immediately before (trough concentrations) and 10 h after (peak concentrations) each diclazuril administration and analysed by high-pressure liquid chromatography. The mean population-derived peak concentration was 0.284 μg/mL and the mean terminal half-life was 1.6 days, but with a large variation. Thus, low dose diclazuril pellets produce steady-state plasma drug concentrations known to inhibit S. neurona (0.001 μg/mL) and N. caninum (0.1 μg/mL).

Original languageEnglish (US)
Pages (from-to)74-76
Number of pages3
JournalVeterinary Journal
Volume242
DOIs
StatePublished - Dec 1 2018

Keywords

  • Diclazuril
  • EPM
  • Prevention
  • Sarcocystis neurona

ASJC Scopus subject areas

  • Animal Science and Zoology
  • veterinary(all)

Fingerprint Dive into the research topics of 'Diclazuril nonlinear mixed-effects pharmacokinetic modelling of plasma concentrations after oral administration to adult horses every 3–4 days'. Together they form a unique fingerprint.

  • Cite this